Find disease awareness content and relevant supporting materials
Brilacidin ,a defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.- Innovation Pharma
Innovation Pharmaceuticals announced that brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral properties, is to be evaluated for its treatment potential against the monkeypox virus.
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Primary analyses of a study in young women aged 16-26 years showed efficacy of the nine-valent human papillomavirus (9vHPV; HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine against infections...
Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract illness in young children and a major cause of hospital admissions globally.